These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37051886)

  • 21. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
    Lawrence I; Moy R
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.
    Frampton JE; Easthope SE
    Am J Clin Dermatol; 2003; 4(10):709-25. PubMed ID: 14507232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Kaufman-Janette J; Avelar RL; Biesman BS; Draelos ZD; Gross JE; Jones DH; Lupo MP; Maas CS; Schlessinger J; Shamban AT; Sundaram H; Weinkle SH; Young VL
    Aesthet Surg J; 2021 Nov; 41(12):1409-1422. PubMed ID: 33944905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Lorenc ZP; Adelglass JM; Avelar RL; Baumann L; Beer KR; Cohen JL; Cox SE; Dayan SH; Dover JS; Downie JB; Draelos ZD; Goldman MP; Gross JE; Joseph JH; Kaufman-Janette J; Moy RL; Nestor M; Schlessinger J; Smith SR; Weiss RA
    Aesthet Surg J; 2021 Nov; 41(12):1423-1438. PubMed ID: 33944913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ; Ascher B; Avelar RL; Bergdahl J; Bertucci V; Bodokh I; Carruthers JA; Cartier H; Delmar H; Denfeld R; Gross JE; Heckmann M; Hedén P; Hilton S; Inglefield C; Ogilvie P; Sattler G; Sebastian M; Solish N; Swift A; Trévidic P
    Aesthet Surg J; 2020 Mar; 40(4):413-429. PubMed ID: 30951166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
    Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
    J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional Analyses From a Phase 2, Randomized, Dose-Ranging, Double-Blind, Multicenter Study.
    Bertucci V; Humphrey S; Carruthers J; Solish N; Muhn C; Swift A; Rubio RG; Shears G; Rosen N
    Dermatol Surg; 2017 Dec; 43 Suppl 3():S262-S273. PubMed ID: 33065952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position.
    Bertucci V; Green JB; Fezza JP; Brown J; Gallagher CJ; Solish N
    Aesthet Surg J; 2023 Nov; 43(Suppl 1):S10-S18. PubMed ID: 36322141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data.
    Cox SE; Ascher B; Avelar RL; Beer KR; Carruthers J; Cartier H; Fagien S; Solish N
    J Cosmet Dermatol; 2023 Jun; 22(6):1745-1756. PubMed ID: 37102990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.
    Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M
    J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin type A for facial wrinkles.
    Camargo CP; Xia J; Costa CS; Gemperli R; Tatini MD; Bulsara MK; Riera R
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD011301. PubMed ID: 34224576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial.
    Afshani SM; Samadi A; Ayatollahi A; Kashani MN; Ahmad Nasdrollahi S; Hosseini H; Rezagholi Z; Hedayatjoo B; Hazegh Fetratjoo D; Ghobadi MA; Anari A; Saeedifar S; Firooz A
    J Cosmet Dermatol; 2022 Jun; 21(6):2398-2406. PubMed ID: 35340107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum Toxin Type A for Glabellar Frown Lines: What Impact of Higher Doses on Outcomes?
    Kaufman-Janette J; Cox SE; Dayan S; Joseph J
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
    Kane MAC; Brandt F; Rohrich RJ; Narins RS; Monheit GD; Huber MB;
    Plast Reconstr Surg; 2009 Nov; 124(5):1619-1629. PubMed ID: 19584772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines.
    Ascher B; Rzany B; Kestemont P; Hilton S; Heckmann M; Bodokh I; Noah EM; Boineau D; Kerscher M; Volteau M; Le Berre P; Picaut P
    Aesthet Surg J; 2020 Jan; 40(1):93-104. PubMed ID: 30893430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.